Summary
Merck & Co., Inc. reported strong financial performance for the first quarter of 2017, with total sales reaching $9.4 billion, a 1% increase year-over-year. This growth was primarily driven by significant contributions from Keytruda in the oncology franchise and the strong performance of the Zepatier hepatitis C treatment, along with a boost from the reintegration of European vaccine sales previously managed through a joint venture. The company also saw positive momentum in its Animal Health division. Despite headwinds from generic competition impacting certain established products like Zetia and Januvia/Janumet, Merck demonstrated resilience through its growing portfolio and strategic initiatives. Net income attributable to Merck & Co., Inc. saw a substantial increase to $1.55 billion ($0.56 per share) from $1.13 billion ($0.41 per share) in the prior year's comparable period. This improvement reflects strong sales performance and effective cost management, though offset by increased restructuring costs and research and development expenses. The company also repurchased $1.0 billion of its stock in the quarter, demonstrating a commitment to returning value to shareholders. Overall, the results indicate a positive trajectory driven by key growth products and strategic portfolio adjustments.
Financial Highlights
51 data points| Revenue | $9.43B |
| Cost of Revenue | $3.05B |
| Gross Profit | $6.38B |
| R&D Expenses | $1.83B |
| SG&A Expenses | $2.47B |
| Interest Expense | $182.00M |
| Net Income | $1.55B |
| EPS (Basic) | $0.56 |
| EPS (Diluted) | $0.56 |
| Shares Outstanding (Basic) | 2.75B |
| Shares Outstanding (Diluted) | 2.77B |
Key Highlights
- 1Total sales increased by 1% to $9.4 billion in Q1 2017 compared to Q1 2016, driven by Keytruda, Zepatier, and vaccine sales from the former SPMSD joint venture.
- 2Net income attributable to Merck & Co., Inc. rose to $1.55 billion ($0.56/share) from $1.13 billion ($0.41/share) year-over-year.
- 3Keytruda sales surged to $584 million from $249 million in the prior year's quarter, signaling strong momentum in the oncology segment.
- 4Zepatier sales increased significantly to $378 million from $50 million, reflecting successful global launches.
- 5The termination of the Sanofi Pasteur MSD (SPMSD) joint venture on December 31, 2016, allowed Merck to record European vaccine sales directly, contributing approximately $65 million in incremental sales.
- 6Animal Health segment sales grew by 13% to $939 million, boosted by products like Bravecto.
- 7The company repurchased $1.0 billion of its common stock in Q1 2017, underscoring its commitment to shareholder returns.